Today: January 17, 2019, 9:12 pm
  
Business

Droia Oncology Ventures raises second fund of EUR 150 million

PR-Inside.com: 2018-12-10 18:54:02

Droia Oncology Ventures raises second fund of EUR 150 million

December 10th 2018: Droia, a specialist investor focused on oncology therapeutics, announced the closing of Droia II, its second fund, at EUR 150 million. Droia II will invest worldwide in early stage drug development companies and in the creation of new companies that apply novel science and innovative approaches to bring the most promising cancer therapies to patients.

Droia’s first fund, Droia I, is now fully allocated to a portfolio of biotech companies in the EU and US, and has already realised its first exits, such as the recent sale of UK-based Tusk Therapeutics to Roche or the IPO of US-based Arcus Biosciences. Droia II was raised to further build on Droia’s proven investment model, which leverages Droia’s in-house oncology expert team to guide and assist portfolio companies in a rapidly evolving landscape. Droia II is supported by the investors of Droia I, who are joined by a series of new institutional and private investors.

Janwillem Naesens, Managing Partner of Droia, comments: “The evolution of our investments in Droia I clearly demonstrates the merits of our investment model. As a testament to this success, Droia II was heavily oversubscribed and closed at more than twice the size of our first fund. This larger fund allows us to expand our investment and in-house expert team, to provide an even wider range of services for our portfolio companies.”

Luc Verelst, Founder of Droia, comments: “We are very grateful for the continued support of our first fund investors, which allowed us to jumpstart the fundraising for the second fund and to complete it in a record time. We also want to welcome our new investors, who have shown great enthusiasm for Droia’s project. We are looking forward to put the new fund to work, help patients and bring value for our investors.”

- Ends -

For further information, please contact:

Droia Oncology Ventures, www.droiagroup.com
Janwillem Naesens, Managing Partner
+32 2 880 67 30
info@droiagroup.com




# 464 Words
Related Articles
More From The Author
Volta Finance Limited: November 2018 Early NAV
Volta Finance Limited (VTA / VTAS) – November 2018 Early NAV NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR [..]
Banks net position in the Riksbank
DEC 10, 2018 SEK MILLION   LENDINGBORROWING244   
Medtronic Named One of America's Best Corporate [..]
DUBLIN - December 10, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has been [..]
The Graduate Management Admission Council Selects Three [..]
Schools Bring Expertise and Insight in Support of GMAC MissionRESTON, Va., Dec. 10, 2018 (GLOBE NEWSWIRE) -- The Graduate Management [..]
Doc re. GE Files Form 8-K
FAIRFIELD, Conn., Dec. 10, 2018 (GLOBE NEWSWIRE) -- CompanyGeneral Electric CompanyISINUS3696041033SymbolLondon: GEC | Paris: GNEHeadlineDoc [..]
 
More From Business
3,300+ Finance, Business Leaders Join Asian Financial [..]
HONG KONG, Jan 16, 2019 - (ACN Newswire) - More than 3,300 financial policymakers, financial elites and business leaders attended [..]
The Executive Talk: Chememan PCL (SET:CMAN)
BANGKOK, Jan 15, 2019 - (ACN Newswire) - Chememan PCL (SET:CMAN) Chief Executive Officer, Mr. Adisak Lowjun discusses the company's [..]
Sapphire's Subsidiary Awarded EPC Contract of RMB [..]
SINGAPORE, Jan 15, 2019 - (ACN Newswire) - SGX Mainboard-listed Sapphire Corporation Limited ("Sapphire", and together [..]
Hong Kong Investment Promotion chief visits London [..]
HONG KONG, Jan 14, 2019 - (ACN Newswire) - The Director-General of Investment Promotion of the Hong Kong Special Administrative [..]
Wildfire Design & Build Receives 2018 Best [..]
NAPA December 13, 2018 -- Wildfire Design & Build has been selected for the 2018 Best of Napa Award in [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.